Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) has shared an announcement.
Lumos Diagnostics has achieved a key enrollment milestone in its BARDA-funded paediatric clinical study evaluating the FebriDx rapid test in children aged 2 to 12 years. This milestone completion triggers a US$720,000 payment, bringing total milestone receipts for the study to US$1.92 million out of a potential US$6.2 million tied to 12 predefined project events.
The study is designed to support U.S. regulatory expansion of FebriDx into CLIA-waived settings and paediatric use, building on its current FDA 510(k) clearance for patients aged 12 to 64 years in urgent and emergency care. If successful, the expanded indications and CLIA waiver would substantially increase Lumos’ addressable U.S. market, opening access to hundreds of thousands of additional clinical sites and providing clinicians treating younger children with an additional tool to differentiate bacterial from non-bacterial acute respiratory infections.
The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.29 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Ltd is an Australian-based company specializing in rapid, point-of-care diagnostic technologies. It develops, manufactures, and commercializes proprietary tests such as FebriDx, along with customized assay development, manufacturing services, and digital reader platforms focused on infectious and inflammatory diseases for clinical settings.
Average Trading Volume: 4,091,133
Technical Sentiment Signal: Buy
Current Market Cap: A$226.1M
For detailed information about LDX stock, go to TipRanks’ Stock Analysis page.